Belantamab mafodotin in patients with severely impaired renal function: a phase I, 2-part study to evaluate pharmacokinetics, safety and efficacy in patients with relapsed/refractory multiple myeloma

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA(2023)

引用 0|浏览5
暂无评分
关键词
relapsed/refractory multiple myeloma,pharmacokinetics,renal function
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要